Enter your information to understand your free psa levels.

The History of Free PSA

Once PSA testing became genuinely widespread throughout the 1980s, doctors quickly noticed a genuinely frustrating limitation: many men with only mildly elevated total PSA turned out to have benign prostate enlargement rather than cancer, yet the test alone couldn't reliably distinguish between these two very different underlying conditions. American urologist William Catalona and his research team at Washington University addressed this exact problem in a landmark 1995 study, demonstrating that PSA actually circulates in two distinct forms, freely unbound or chemically complexed to certain blood proteins, and that men with prostate cancer tend to have a notably lower percentage of free, unbound PSA than men with benign prostate enlargement. This discovery gave doctors a genuinely valuable additional tool for deciding which men with borderline PSA results actually needed a prostate biopsy, meaningfully reducing the number of unnecessary invasive procedures performed on patients nationwide each and every year.

What Free PSA % Actually Is

Free PSA percentage represents exactly what fraction of a man's total circulating PSA exists in its unbound, freely circulating form, as opposed to the remaining portion that's chemically bound to specific blood proteins like alpha-1-antichymotrypsin. Prostate cancer cells tend to produce relatively more of the protein-bound form of PSA compared to healthy or benign prostate tissue, meaning a lower percentage of free PSA statistically correlates with a meaningfully higher probability that cancer, rather than benign enlargement, is genuinely driving an elevated total PSA result. This percentage becomes particularly useful clinically when total PSA falls into an ambiguous "gray zone," typically between four and ten nanograms per milliliter, where the standard test alone otherwise cannot reliably distinguish genuine cancer from benign disease.

How Free PSA % Is Measured

Free PSA percentage requires two separate immunoassay measurements performed on the very same blood sample: one measuring total PSA, capturing both bound and unbound forms together, and a second measuring only the freely circulating, unbound fraction specifically. Laboratories then simply divide the free PSA value by the total PSA value and multiply by one hundred to calculate the final percentage reported to the ordering physician. Because this calculation depends on two separate, carefully calibrated assays working together accurately, doctors generally interpret free PSA percentage results only when both underlying values were measured using the very same laboratory testing platform and equipment.

Scientists Behind the Science

William Catalona's landmark 1995 research fundamentally transformed how doctors interpret borderline PSA results, giving urologists a genuinely practical, statistically validated way to meaningfully reduce unnecessary prostate biopsies performed on men with benign, non-cancerous conditions. His painstaking clinical research, involving careful comparison of free and total PSA levels across large groups of both cancer and non-cancer patients, established the specific percentage thresholds still routinely used in urology clinics and hospitals worldwide today. Catalona's work represents a genuinely important refinement built directly upon Richard Ablin's original PSA discovery, demonstrating how a single biomarker can be genuinely and meaningfully improved decades after its initial identification through careful, dedicated clinical research and follow-up study.